Latest Insider Transactions at Enanta Pharmaceuticals Inc (ENTA)
This section provides a real-time view of insider transactions for Enanta Pharmaceuticals Inc (ENTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ENANTA PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ENANTA PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-7.24%
|
$17,592
$12.73 P/Share
|
|
Jul 15
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,375
-19.84%
|
$91,375
$17.08 P/Share
|
|
Jul 15
2024
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,375
+16.56%
|
$43,000
$8.99 P/Share
|
|
Jul 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,271
-9.47%
|
$34,065
$15.04 P/Share
|
|
Jul 11
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,299
-15.2%
|
$64,485
$15.07 P/Share
|
|
Jun 17
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,266
-18.35%
|
$87,192
$12.33 P/Share
|
|
Feb 26
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,187
+6.41%
|
$41,496
$8.99 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-2.4%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+7.56%
|
-
|
|
Feb 12
2024
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-2.43%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+7.65%
|
-
|
|
Feb 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
755
-2.6%
|
$9,060
$12.41 P/Share
|
|
Feb 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,576
+8.15%
|
-
|
|
Feb 12
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-1.36%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+4.44%
|
-
|
|
Feb 12
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,080
-0.29%
|
$12,960
$12.41 P/Share
|
|
Feb 12
2024
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,680
+0.97%
|
-
|
|
Feb 12
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-1.0%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+3.31%
|
-
|
|
Feb 12
2024
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,584
-0.2%
|
$19,008
$12.41 P/Share
|
|
Feb 12
2024
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,400
+0.66%
|
-
|
|
Dec 13
2023
|
Terry Vance Director |
SELL
Open market or private sale
|
Direct |
15,295
-72.51%
|
$137,655
$9.12 P/Share
|
|
Dec 05
2023
|
Brendan Luu Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,125
-5.47%
|
$19,125
$9.63 P/Share
|
|
Dec 05
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,412
-3.42%
|
$21,708
$9.63 P/Share
|
|
Dec 05
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,125
-5.4%
|
$19,125
$9.63 P/Share
|
|
Dec 05
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
2,412
-2.51%
|
$21,708
$9.63 P/Share
|
|
Dec 05
2023
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,412
-0.65%
|
$21,708
$9.63 P/Share
|
|
Dec 05
2023
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
534
-1.98%
|
$4,806
$9.63 P/Share
|
|
Dec 05
2023
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
7,230
-0.89%
|
$65,070
$9.63 P/Share
|
|
Dec 01
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-1.88%
|
$6,777
$9.49 P/Share
|
|
Dec 01
2023
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-1.9%
|
$6,777
$9.49 P/Share
|
|
Dec 01
2023
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-0.43%
|
$14,355
$9.49 P/Share
|
|
Dec 01
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-2.21%
|
$14,355
$9.49 P/Share
|
|
Dec 01
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-1.64%
|
$14,355
$9.49 P/Share
|
|
Dec 01
2023
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,787
-0.71%
|
$52,083
$9.49 P/Share
|
|
Aug 08
2023
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,467
-5.43%
|
$24,939
$17.23 P/Share
|
|
Apr 18
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+7.69%
|
$200,010
$30.0 P/Share
|
|
Mar 16
2023
|
Terry Vance Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,800
+21.57%
|
$81,200
$14.0 P/Share
|
|
Mar 15
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
10,440
-4.84%
|
$459,360
$44.2 P/Share
|
|
Mar 15
2023
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,440
+8.81%
|
$146,160
$14.0 P/Share
|
|
Mar 15
2023
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
13,925
-1.79%
|
$612,700
$44.19 P/Share
|
|
Mar 15
2023
|
Yat Sun Or Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,925
+3.46%
|
$194,950
$14.0 P/Share
|
|
Mar 13
2023
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
27,912
-1.11%
|
$1,256,040
$45.42 P/Share
|
|
Mar 13
2023
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,912
+3.19%
|
$390,768
$14.0 P/Share
|
|
Feb 13
2023
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,416
-13.94%
|
$333,632
$52.77 P/Share
|
|
Feb 13
2023
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,305
+20.15%
|
-
|
|
Feb 13
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,735
-8.41%
|
$350,220
$52.77 P/Share
|
|
Feb 13
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,997
+12.36%
|
-
|
|
Feb 13
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,725
-14.35%
|
$349,700
$52.77 P/Share
|
|
Feb 13
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,997
+20.45%
|
-
|